The team discovered that, when CUX1 is deactivated, a biological pathway is activated that increases tumour growth. Drugs that inhibit the biological pathway are currently being used in the clinic and are in development thus highlighting a potential new targeted therapy for patients with this type of cancer-causing mutation. …
Recent studies from several countries have reported rising incidence of oropharyngeal cancers and subsequent studies have shown the human papilloma virus (HPV) as the potential cause. However, it has been unclear whether this increase in oropharyngeal cancer incidence represents a global phenomenon…
"We know very little about male breast cancer since it comprises only 0.6 percent of all breast cancer, and nearly all therapy is based on female breast cancer studies. This study demonstrates that just as in women, men with early stage breast cancer have the same outcome with a mastectomy or a lumpectomy followed by radiation. In women, breast-conserving surgery is the standard and preferred treatment for the majority of women…
The novel therapeutic, which is based on nanotechnology, is small and nimble enough to cross the blood-brain barrier and get to where it is needed — the brain tumor. Designed to target a specific cancer-causing gene in cells, the drug simply flips the switch of the troublesome oncogene to "off," silencing the gene…
In addition to identifying a gene that raises risk for colorectal cancer from eating red or processed meat, the study — the first to identify the interactions of genes and diet on a genome-wide scale — also reveals another specific genetic variation that appears to modify whether eating more vegetables, fruits and fiber actually lowers your colorectal cancer risk. …
About 50 percent of melanomas, and less frequently other cancer types, harbor mutations in the BRAF oncogene. …
When there is damage to DNA in human cells, two proteins, PARP 1 and 2, recruit proteins that can repair the damage associated with loss of BRCA proteins. Mutations in BRCA genes often result in inefficient repair of damaged DNA, which increases the risk for developing certain cancers, including cancers of the breast and ovary. Inhibiting PARP, therefore, prevents the repair of damaged DNA, leading to cell death. …
"By itself, staurosporine shows potent activity against a number of cancer cell lines, including chemotherapy-resistant tumors. However, it also harms normal tissue," said senior author Santosh Kesari, MD, PhD, director of neuro-oncology at UC San Diego Moores Cancer Center. "With this study, we have been able to overcome the pharmacokinetic barriers to delivering staurosporine to tumors with the use of liposomes." STS was originally isolated from the bacterium Streptomyces staurosporeus in 1977. The compound prompts a wide variety of cancer cell types to self-destruct, a process called apoptosis or programmed cell death. …
Antibody-drug conjugates are a new type of targeted anticancer therapy, which use an antibody to deliver an attached drug directly to those cells that display the antibody’s target on their surfaces. This precision reduces the side effects of the attached drug compared with conventional systemic administration. Currently, there are two U.S…
Mutations in the growth factor gene EGFR are present in about 10 to 15 percent of patients with the most common form of lung cancer, non-small cell lung cancer (NSCLC). Most NSCLCs harboring these EGFR mutations, called activating mutations, respond to the EGFR inhibitor drugs erlotinib and gefitinib. A majority of such cancers, however, develop resistance to these drugs within about nine to 11 months. …